Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Healthy Volunteer

What is this?
A volunteer subject with no known significant health problems who participates in research to test a new drug, device or intervention. These volunteers are recruited to serve as controls for patient groups. Healthy volunteers receive the same test, procedure, or drug the patient group receives.

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 481-490 of 2932 for cancer

Edit search filters
  1. Durvalumab And Grid Therapy For The Treatment Of Non-small Cell Lung Cancer In Patients Who Progressed During Or After Treatment With The PACIFIC Regimen

    Rochester, MN

  2. Adding The Immunotherapy Drug Cemiplimab To Usual Treatment For People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy And Immunotherapy (An Expanded Lung-MAP Treatment Trial)

    Rochester, MN

  3. Veliparib And Combination Chemotherapy In Treating Patient With Locally Advanced Rectal Cancer

    Jacksonville, FL, Rochester, MN

  4. Oxaliplatin, Leucovorin Calcium, and Fluorouracil with or without Celecoxib in Treating Patients with Stage III Colon Cancer Previously Treated with Surgery

    Eau Claire, WI

  5. Testing The Addition Of The Drug Atezolizumab To The Usual Radiation Treatment For Patients With Early Non-small Cell Lung Cancer

    La Crosse, WI

  6. Clinical Trial Of SP-2577 (Seclidemstat) In Patients With Relapsed Or Refractory Ewing Or Ewing-related Sarcomas

    Jacksonville, FL, Rochester, MN

  7. GMCI Plus Standard Of Care Immune Checkpoint Inhibitor For Stage III/IV NSCLC

    Rochester, MN

  8. NRG-GY012 “A Randomized Phase II Study Comparing Single-Agent Olaparib, Single Agent Cediranib, And The Combinations Of Cediranib/Olaparib, Olaparib/Durvalumab (MEDI4736), Cediranib/Durvalumab (MEDI4736), Olaparib/AZD5356 (Capivasertib) In Women With Recurrent, Persistent Or Metastatic Endometrial Cancer. A Multi-Arm Trial For Women With Recurrent Or Persistent Endometrial Cancer”

    Scottsdale/Phoenix, AZ, Eau Claire, WI, Rochester, MN

  9. A Phase I/II, Open-label, Multi-center Trial Of [177Lu]Lu-NeoB In Combination With Capecitabine In Adult Patients With GRPR+, ER+, HER2- Metastatic Breast Cancer After Progression On Previous Endocrine Therapy In Combination With A CDK4/6 Inhibito

    Rochester, MN

  10. A Study Of Multiple Therapies In Biomarker-Selected Patients With Resectable Stages IB-III Non-Small Cell Lung Cancer

    Rochester, MN

.

Mayo Clinic Footer